Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases requiring medical intervention. Co.'s product pipeline consists of: VP-102, which is a propriety drug-device combination that contains a good manufacturing practices-controlled formulation of cantharidin which is being developed for potential use in treating molluscum contagiosum, external genital warts and common warts; VP-315, which is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma; and VP-103, which is a cantharidin based drug device combination for the potential treatment of plantar warts. The VRCA YTD return is shown above.
The YTD Return on the VRCA YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VRCA YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VRCA YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|